Cetuximab

Interleukin-1 alpha increases anti-tumor efficacy of cetuximab in head and neck squamous cell carcinoma
Madelyn Espinosa-Cotton, Samuel N. Rodman III, Kathleen A. Ross, Isaac J. Jensen, Kenley Sangodeyi-Miller, Ayana J. McLaren, Rachel A. Dahl, Katherine N. Gibson-Corley, Adam T. Koch, Yang-Xin Fu, Vladimir P. Badovinac, Douglas Laux, Balaji Narasimhan, Andrean L. Simons

Journal for ImmunoTherapy of Cancer Dec 2019, 7 (1) 79; DOI: 10.1186/s40425-019-0550-z
PD-1 is a marker of activation on tumor infiltrating NK cells in head and neck cancer
Fernando Concha-Benavente, Raghvendra M Srivastava, Benjamin Kansy, Robert L Ferris

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P398; DOI: 10.1186/2051-1426-3-S2-P398
Anti-EGFR mAb cetuximab therapy increases T cell receptor (TCR) diversity in the peripheral blood and focuses TCR richness in the tumor microenvironment
Benjamin A Kansy, Yan Lin, Fei Ding, Sandra Poveda Gibson, Hyun-Bae Jie, Robert L Ferris

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P73; DOI: 10.1186/2051-1426-3-S2-P73
A Phase Ib study of neoadjuvant immune biomarker modulation with cetuximab and motolimod in head and neck cancer (HNC)
Robert L Ferris, Benjamin A Kansy, Sandra Poveda Gibson, Raghvendra M Srivastava, James Kyle Bryan, Robert M Hershberg

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P144; DOI: 10.1186/2051-1426-3-S2-P144
The mAbXcite platform modifies the tumor microenvironment when applied to an immune-oncology anti-CTLA4 antibody
Isabelle Sansal-Castellano, Mark Carlson, Gabriel Reznik, James Siedlecki, John Kane, Zuzana Dostalova, Hua Miao, Ifat Rubin-Bejerano

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P414; DOI: 10.1186/2051-1426-3-S2-P414
Reovirus activated NK cells show enhanced cetuximab mediated antibody-dependent cellular cytotoxicity against colorectal cancer cells
Xing Zhao, Narendiran Rajasekaran, Cariad Chester, Atsushi Yonezawa, Suparna Dutt, Matt Coffey, Holbrook E Kohrt

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P340; DOI: 10.1186/2051-1426-3-S2-P340
Anti-EGFR targeted monoclonal antibody isotype influences anti-tumor immunity in head and neck cancer patients
Sumita Trivedi, Raghvendra M Srivastava, Fernando Concha-Benavente, Tatiana M Garcia-Bates, Jing Li, Robert L Ferris

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P316; DOI: 10.1186/2051-1426-3-S2-P316
Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle
Robert L Ferris, Caroline Even, Robert Haddad, Makoto Tahara, Trishna Goswami, April Franks, Ugochi Emeribe, Anthony Jarkowski, Giovanni Melillo, Lisa Licitra

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P150; DOI: 10.1186/2051-1426-3-S2-P150
Lower toxicity and higher efficacy: a study on a novel fully human anti-EGFR antibody
Weiyi Qiu, Shuang Wang

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P241; DOI: 10.1186/2051-1426-3-S2-P241
Interleukin-21 activates natural killer cell activity against cetuximab-coated pancreatic tumor cells
Elizabeth L McMichael, Alena Cristin Jaime-Ramirez, Kristan Guenterberg, Eric Luedke, Lakhvir Atwal, William E Carson

Journal for ImmunoTherapy of Cancer Dec 2015, 3 (Suppl 2) P233; DOI: 10.1186/2051-1426-3-S2-P233

Main menu

Cetuximab

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Cetuximab

Pages